Publications by authors named "Mariana Silveira de Alcantara Chaud"
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trial.
Pedro Gabriel Melo de Barros E Silva Remo H M Furtado Mariana Silveira de Alcântara Chaud Ariane Vieira Scarlatelli Macedo Bruna Bronhara
J Thromb Thrombolysis
August 2024
Article Synopsis
- Therapeutic anticoagulation in COVID-19 patients shows mixed outcomes, complicating the selection of suitable patients due to balancing thrombotic and bleeding risks.
- A post-hoc analysis of the ACTION trial examined factors linked to bleeding and thrombotic events, using logistic regression to identify significant variables.
- Key findings included that non-invasive respiratory support related to thrombotic risks, invasive ventilation increased risks for both outcomes, and factors like creatinine levels and a history of coronary disease were important in determining thrombotic risk.
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D Lopes Pedro Gabriel Melo de Barros E Silva Remo H M Furtado Ariane Vieira Scarlatelli Macedo Bruna Bronhara Mariana Silveira de Alcântara Chaud
Lancet
June 2021
Background: COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population.
View Article and Find Full Text PDF